A phase I/II open-label study of AMG-706 given orally in combination with standard concurrent chemoradiation regimen (cisplatin/etoposide/radiation) in stage IIIA/B non-small cell lung cancer (NSCLC)
Latest Information Update: 11 May 2007
At a glance
- Drugs Motesanib (Primary) ; Cisplatin; Etoposide
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 11 May 2007 New trial record.